Keryx Biopharma (KERX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
August 6, 2015 10:01 AM EDTBTIG earlier downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Sell with a price target of $3.50. The change follows Q2 results. Analyst Hartaj Sing pointed out revenue weakness.
"We are downgrading Keryx from a Neutral to a Sell with a $3.50 price target after the... More
Keryx Biopharmaceuticals (KERX) PT Cut to $22 at Brean Capital Following Q2; Upside Seen Over 200%
August 5, 2015 12:06 PM EDTBrean Capital analyst Jonathan Aschoff lowered his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) to $22.00 (from $26.00) following Q2 results but maintained a Buy rating as the new price target still suggests 224% upside from current levels. The analyst expects more meaningful Auryxia sales to come in 2H15.
Aschoff commented, "Keryx reported 2Q15 total revenue of $2.5 million, versus consensus of $2.9 million, but we expect more... More
